Ashwani Verma
Stock Analyst at UBS
(3.44)
# 919
Out of 5,008 analysts
87
Total ratings
51.56%
Success rate
4.8%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $560 → $580 | $456.84 | +26.96% | 8 | Sep 29, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $23 → $26 | $20.07 | +29.55% | 10 | Sep 24, 2025 | |
| BHVN Biohaven | Maintains: Buy | $27 → $26 | $15.02 | +73.10% | 4 | Sep 16, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $36 → $39 | $21.54 | +81.06% | 7 | Sep 9, 2025 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $13 → $20 | $14.47 | +38.22% | 3 | Aug 21, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $133 → $144 | $118.64 | +21.38% | 5 | Aug 6, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $43 → $38 | $39.63 | -4.11% | 4 | Jul 30, 2025 | |
| IMVT Immunovant | Maintains: Neutral | $17 → $18 | $16.11 | +11.73% | 1 | Jul 28, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $152 → $174 | $137.00 | +27.01% | 9 | Jul 9, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $60 → $54 | $31.41 | +71.92% | 3 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $30.95 | +35.70% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $61 | $87.17 | -30.02% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $60.17 | -31.86% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $48 | $27.05 | +77.45% | 2 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.71 | -38.60% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $179 | $137.32 | +30.35% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $85.21 | +33.79% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $36.10 | -22.44% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $113.56 | -93.84% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $10.14 | +18.34% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.50 | +2,901.80% | 1 | Oct 11, 2022 |
United Therapeutics
Sep 29, 2025
Maintains: Buy
Price Target: $560 → $580
Current: $456.84
Upside: +26.96%
Teva Pharmaceutical Industries
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $20.07
Upside: +29.55%
Biohaven
Sep 16, 2025
Maintains: Buy
Price Target: $27 → $26
Current: $15.02
Upside: +73.10%
ACADIA Pharmaceuticals
Sep 9, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $21.54
Upside: +81.06%
Avadel Pharmaceuticals
Aug 21, 2025
Maintains: Buy
Price Target: $13 → $20
Current: $14.47
Upside: +38.22%
Axsome Therapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $133 → $144
Current: $118.64
Upside: +21.38%
Exelixis
Jul 30, 2025
Maintains: Neutral
Price Target: $43 → $38
Current: $39.63
Upside: -4.11%
Immunovant
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $16.11
Upside: +11.73%
Neurocrine Biosciences
Jul 9, 2025
Maintains: Buy
Price Target: $152 → $174
Current: $137.00
Upside: +27.01%
Legend Biotech
Jul 2, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $31.41
Upside: +71.92%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $30.95
Upside: +35.70%
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $87.17
Upside: -30.02%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $60.17
Upside: -31.86%
Apr 28, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $27.05
Upside: +77.45%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.71
Upside: -38.60%
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $137.32
Upside: +30.35%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $85.21
Upside: +33.79%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $36.10
Upside: -22.44%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $113.56
Upside: -93.84%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $10.14
Upside: +18.34%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.50
Upside: +2,901.80%